After 2 Plasma Donor Deaths, Company Pauses Clinics in Canada

What the report says

Grifols, the Spanish blood-products company, has temporarily paused plasma collection at 17 clinics in Canada after what it described as heightened and unwarranted attention on its business there. The move follows the deaths of two plasma donors, which have drawn scrutiny to the company’s operations and to the broader safety of paid plasma collection.

The New York Times reports that the company said the attention had become a factor in its decision to halt collections. The clinics are in Canada, but the available source material does not specify all locations or give a detailed timeline for the pauses beyond the temporary suspension.

The development matters because plasma collected at such centers is used to make medicines for people with immune disorders and other conditions, and any interruption can affect supply. More broadly, the episode adds to ongoing debates in Canada and elsewhere about donor safety, oversight of plasma clinics, and the role of private companies in collecting blood components.

Based on general background, plasma donation is usually tightly regulated, but standards and compensation models can vary by country. The source evidence does not provide a ruling on fault or any official findings about the donor deaths, so those details remain unclear.